Ensysce Biosciences, Inc. operates as a clinical stage biotech company. The Company focuses on stemming the prescription drug abuse epidemic. Ensysce Biosciences serves customers worldwide.

S-3 | Registration statement for specified transactions by certain issuers

Annual Report to Security Holders (Form ARS | Period ending 2024-12-31)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ensysce Biosciences (ENSC US)

S-3 | Registration statement for specified transactions by certain issuers

Annual Report to Security Holders (Form ARS | Period ending 2024-12-31)

Current Report (Form 8-K | Period ending 2025-11-17)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Current Report (Form 8-K | Period ending 2025-11-14)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)